Brain scans reveal how cytisinicline may quiet smoking urges

NCT ID NCT06617312

Recruiting now Knowledge-focused Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether the drug cytisinicline changes how the brain reacts to seeing smoking-related images in daily smokers who are not trying to quit. Sixty-four participants will receive either the drug or a placebo and undergo brain scans while watching videos of smoking and non-smoking cues. The goal is to understand the brain mechanisms behind reduced cravings, which could inform better treatments for tobacco use disorder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytisinicline
What this could lead to: If successful, this could reveal how cytisinicline changes brain activity related to smoking cravings, pointing toward a more effective quit-smoking aid.
What could go wrong: This is an early-phase lab study with only 64 participants who are not trying to quit, so results may not translate to real-world quitting success or apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOKING CESSATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cigarette Smoking nicotine dependence Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMOKING CESSATION TOBACCO USE DISORDER

Contacts and locations

Locations

University of California Los Angeles
RECRUITING

Los Angeles, California, 90049, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.